The value of adjuvant misonidazole in the definitive irradiation of advanced head and neck squamous cancer: an RTOG pilot study (#78-02).
D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000532:radiotherapy*; D004341:Drug Evaluation; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy / Q000532:radiotherapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D008920:Misonidazole / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D009062:Mouth Neoplasms / Q000532:radiotherapy; D009325:Nausea / Q000209:etiology; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D009593:Nitroimidazoles / Q000627:therapeutic use*; D010292:Paresthesia / Q000209:etiology; D010610:Pharyngeal Neoplasms / Q000532:radiotherapy; D011379:Prognosis
D009593:Nitroimidazoles; D008920:Misonidazole